Gene expression diagnostics tools for accurate identification, sub-typing and prognosis. Cancers targeted initially are rhabdomyosarcoma, lymphoma, Ewing’s Sarcoma, and neuroblastoma. Additional cancer types will be added in later stages of development.❖ Evidence-Based Medicine:
1. Direct sequencing of genes known to be activated in cancer and have an existing targeted drug that is either FDA-approved, enrolled in Phase II & III clinical trials, or subjected to the Pediatric Preclinical Testing Program. Potential drug candidates will be test on the patient’s tumor cells for responsiveness.
2. Treatment guidance platform for cancers refractory to current “standards of care”. The platforms will identify the molecular biology driving the patient’s cancer and guide physicians to the most germane and effective treatment specific to that patient.❖ Target Identification:
Whole exome sequencing of matched tumor/normal samples to identify drug targets for rare childhood, adolescent and yound adults caners.❖ Pediatric Cancer Commons:
A web-based open-science community; therapy decision support tool. Molecular disease models developed by The Nicholas Conor Instiute will inform physicians, patients, and scientists of the most recent scientific developments, availability of diagnostic tools and ongoing clinical trials.
THE NICHOLAS CONOR INSTITUTE
3525 Del Mar Heights Road, #946•San Diego, California 92130